Physician profile
Justin Wu
NPI 1174824841
$9,927.41
in general payments reported to CMS, 2019-2025
31 companies · $879 in 2025
The $879 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,136 · 2020: $110 · 2021: $384 · 2022: $723 · 2023: $995 · 2024: $2,700 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,240.77 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $1,457.30 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Horizon Therapeutics Plc | $991.93 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $670.12 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $574.22 | 2019 | |
| Glaxosmithkline, LLC. | $570.90 | 2019-2025 | Benlysta |
| Pfizer INC. | $497.30 | 2019-2024 | |
| Ucb, INC. | $471.24 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $343.68 | 2019-2024 | Tremfya |
| Radius Health, INC. | $299.99 | 2019-2024 | Tymlos |
| Celgene Corporation | $265.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $244.78 | 2019-2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $212.40 | 2019-2024 | Orencia |
| Lilly USA, LLC | $135.24 | 2019-2024 | Taltz, Zepbound |
| Genzyme Corporation | $133.69 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $114.93 | 2023-2025 | Lupkynis |
| Medexus Pharma, INC. | $94.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.69 | 2019-2024 | Ofev |
| Organon LLC | $89.17 | 2024 | |
| Genentech USA, INC. | $83.45 | 2019-2023 | Actemra |
| Mallinckrodt Hospital Products INC. | $60.24 | 2023-2024 | Acthar |
| Fresenius Kabi USA, LLC | $55.23 | 2024 | Idacio |
| Sanofi-Aventis U.S. LLC | $40.33 | 2019 | |
| Hikma Pharmaceuticals USA | $39.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.25 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $28.48 | 2024 | Opsumit, Uptravi |
| Zimmer Biomet Holdings, INC. | $23.61 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Depuy Synthes Sales INC. | $20.04 | 2023 | Orthovisc |
| Merck Sharp & Dohme LLC | $16.48 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.01 | 2024 | |
| Fidia Pharma USA INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.